BioScrip, Inc. (NASDAQ:BIOS) Director Michael G. Bronfein sold 27,000 shares of BioScrip stock in a transaction on Friday, September 15th. The shares were sold at an average price of $2.69, for a total transaction of $72,630.00. Following the completion of the transaction, the director now directly owns 129,669 shares of the company’s stock, valued at approximately $348,809.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of BioScrip, Inc. (NASDAQ BIOS) traded down 5.20% during mid-day trading on Tuesday, hitting $2.55. 1,087,939 shares of the stock traded hands. The firm’s market cap is $325.06 million. BioScrip, Inc. has a 12-month low of $0.98 and a 12-month high of $3.43. The firm’s 50 day moving average price is $2.87 and its 200 day moving average price is $2.28.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.01). The business had revenue of $218.11 million for the quarter, compared to the consensus estimate of $220.05 million. The business’s revenue was down 6.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.14) EPS. On average, equities research analysts predict that BioScrip, Inc. will post ($0.55) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://theolympiareport.com/2017/09/19/bioscrip-inc-bios-director-sells-72630-00-in-stock.html.

A number of research firms have weighed in on BIOS. Zacks Investment Research cut shares of BioScrip from a “buy” rating to a “hold” rating in a report on Monday, August 14th. SunTrust Banks, Inc. raised shares of BioScrip from a “hold” rating to a “buy” rating and lifted their price objective for the company from $3.25 to $3.75 in a report on Thursday, August 10th. BidaskClub cut shares of BioScrip from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. Barrington Research lifted their price objective on shares of BioScrip to $3.50 and gave the company an “outperform” rating in a report on Monday, June 26th. Finally, ValuEngine cut shares of BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $3.75.

A number of institutional investors have recently made changes to their positions in BIOS. Teachers Advisors LLC raised its position in BioScrip by 14.0% during the 4th quarter. Teachers Advisors LLC now owns 162,778 shares of the company’s stock worth $169,000 after buying an additional 20,000 shares during the last quarter. Wells Fargo & Company MN raised its position in BioScrip by 1.1% during the 1st quarter. Wells Fargo & Company MN now owns 113,710 shares of the company’s stock worth $193,000 after buying an additional 1,254 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of BioScrip by 7.6% in the 1st quarter. Bank of New York Mellon Corp now owns 475,844 shares of the company’s stock valued at $809,000 after purchasing an additional 33,453 shares in the last quarter. Alambic Investment Management L.P. purchased a new position in shares of BioScrip in the 1st quarter valued at about $160,000. Finally, American International Group Inc. increased its holdings in shares of BioScrip by 73.8% in the 1st quarter. American International Group Inc. now owns 67,812 shares of the company’s stock valued at $115,000 after purchasing an additional 28,787 shares in the last quarter. Institutional investors own 84.05% of the company’s stock.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.